慢性心力衰竭患者血清lncRNA MALAT1的表达水平及其临床意义

目的 探究慢性心力衰竭(chronic heart failure,CHF)患者血清长链非编码RNA(long non-coding RNA,lncRNA)肺癌转移相关转录本1(MALAT1)的表达水平及其临床意义.方法 选取2017年2月～2019年5月西安高新医院急诊科收治的62例CHF患者为CHF组,另选取同期7...

Expression of lncRNA MALAT1 in Peripheral Blood of Patients with Chronic Heart Failure and Its Clinical Significance

Objective　To explore the expression level of long non-coding RNA (lncRNA) MALAT1 in peripheral blood ofpatients with chronic heart failure (CHF) and its clinical significance. Methods　62 CHF patients admitted to the Department ofEmergency of Xi ’an Gaoxin Hospital from February 2017 to May 2019 were selected as the CHF group, and 70 healthy subjectsduring the same period were selected as the control group. The expression level of lncRNA MALAT1 in serum was detected byreal-time quantitative fluorescence PCR(qRT-PCR). The levels of apoptotic molecules in serum were determined by enzyme-linkedimmunosorbent assay (ELISA). Color Doppler ultrasonography was used to examine and determine the related indexes of heartfailure. The correlation was analyzed by Pearson correlation, receiver operating characteristic (ROC) curve was used to evaluatethe diagnostic efficacy of lncRNA MALAT1 for CHF. Results　The serum lncRNA malAT1 and B-cell lymphoma-2 (Bcl-2) levelsin CHF group were lower than those in the control group, and the serum Bcl2-associated X protein (Bax) levels in CHF group werehigher than those in the control group, the difference were statistically significant (t=16.31, 11.90, 9.57, all P=0.00). Patients withCHF group New York Heart Disease Assocation (NYHA) Ⅲ and Ⅳ serum lncRNA MALAT1 and Bcl-2 levels below theNYHA Ⅱ level, in CHF group NYHA Ⅲ and Ⅳ patients serum Bax levels higher than the NYHA level, NYHA Ⅳ Ⅱlevel in patients with serum lncRNA MALAT1 and Bcl-2 levels below Ⅲ level, the serum Bax level was higher than Ⅲ level,and the difference wars statistically significant (all P<0.05). The left ventricular ejection fraction (LVEF) in CHF group werelower than that in control group, the left ventricular end diastolic diameter (LVEDD) and left ventricular end systolic diameter(LVESD) were higher than those in the control group, the difference were statistically significant (t=4.56~10.85, all P=0.00).Pearson correlation analysis showed that serum lncRNA MALAT1 and Bcl-2 levels in CHF group were positively correlated withLVEF (r=0.29, 0.32, all P<0.05), while negatively correlated with LVEDD and LVESD (r=-0.25, -0.31, P=0.01). Serum Bax inCHF group was negatively correlated with LVEF (r=-0.33, P=0.01), while positively correlated with LVEDD and LVESD(r=0.20, 0.32, all P=0.00). In CHF group, serum lncRNA MALAT1 was positively correlated with the level of Bcl-2 (r=0.31,P=0.00), and negatively correlated with the level of serum Bax (r=-0.24, P=0.01). The area under the curve (AUC) of serumlncRNA MALAT1 in the diagnosis of CHF was 0.791, the sensitivity and the specificity were 75% and 79.5%,respectively(95%CI=0.6533~0.930, P=0.001). Conclusion　The serum lncRNA MALAT1 level was decreased in CHF patients, which canbe used as a potential biomarker to evaluate the disease progression of CHF.